论文部分内容阅读
目的采用FOLFOX4及FOLFOX4加Avastin两种方案治疗转移性结直肠癌,观察两者的疗效。方法选择ECOG功能状态评分在0～2,128例转移性结直肠癌患者,随机分成A、B两组,分别采用FOLFOX4和FOLFOX4加Avastin方案治疗六个周期。结果 A组有81例:完全缓解(CR)1.2%,部分缓解(PR)38.3%,总有效率为(CR+PR)39.5%;B组有47例:CR14.9%,PR61.7%,总有效率为(CR+PR)76.6%。结论 B组有效率明显高于A组,P<0.05,疾病无进展时间(PFS)显著延长。因此,FOLFOX4-AVASTIN生物化疗可以作为转移性结直肠癌的一线化疗方案。
Objective To investigate the curative effect of both the FOLFOX4 and FOLFOX4 plus Avastin in the treatment of metastatic colorectal cancer. Methods The patients with ECOG functional status score of 0 to 2,128 patients with metastatic colorectal cancer were randomly divided into A and B groups and treated with FOLFOX4 and FOLFOX4 plus Avastin for six cycles respectively. Results In group A, there were 81 cases with complete remission (CR) 1.2%, partial remission (PR) 38.3% and total effective rate (CR + PR) 39.5% , The total effective rate was (CR + PR) 76.6%. Conclusion The effective rate in group B is significantly higher than that in group A, P <0.05, and the disease progression-free time (PFS) is significantly prolonged. Therefore, FOLFOX4-AVASTIN biochemotherapy can be used as first-line chemotherapy for metastatic colorectal cancer.